论文部分内容阅读
目的比较替吉奥联合顺铂方案(SP方案)与5-氟尿嘧啶(5-Fu)联合顺铂方案(FP方案)一线治疗晚期胃癌的近期疗效及安全性。方法 50例晚期胃癌患者随机分为2组,观察组(SP组)患者25例,替吉奥联合顺铂治疗:替吉奥40 mg/m2口服,每天2次,第1~14天;顺铂75 mg/m2,静脉滴注,第1天,21 d为1个周期。对照组(FP组)患者25例,5-氟尿嘧啶联合顺铂治疗:顺铂80 mg/m2,静脉滴注,第1天;5-Fu 800 mg/(m2·d)静脉滴注24 h,第1~5天,21d为1个周期。治疗至少2个周期后评价两组患者的近期疗效及不良反应。结果 SP组患者总有效率(RR)为56.0%,其中完全缓解(CR)1例,部分缓解(PR)13例;FP组患者RR为48.0%,其中CR 1例,PR 11例,差异无统计学意义(P>0.05)。但SP组患者的临床受益率(CBR)为84.0%,优于FP组患者的68.0%,差异有统计学意义(P<0.05)。两组患者的不良反应以骨髓抑制、消化道反应、肝功能异常及口腔黏膜炎为主。其中FP组患者的恶心、呕吐反应显著高于SP组。而SP组出现了较高的腹泻发生率,与FP组比较,差异有统计学意义(P<0.05)。结论替吉奥联合顺铂方案一线治疗晚期胃癌疗效肯定,不良反应较轻。
Objective To compare the short-term efficacy and safety of the first-line treatment of advanced gastric cancer with the combination of tegafur with cisplatin (SP) and 5-fluorouracil (5-Fu) with cisplatin (FP). Methods 50 patients with advanced gastric cancer were randomly divided into 2 groups, 25 patients in the observation group (SP group), and the combination of sedico and cisplatin: 40 mg/m2 of Tediool orally twice a day for 1 to 14 days; Platinum 75 mg/m2, intravenous drip, on the first day, 21 days for 1 cycle. 25 patients in the control group (FP group), 5-fluorouracil combined with cisplatin treatment: Cisplatin 80 mg/m2, intravenous drip on the first day; 5-Fu 800 mg/(m2·d) IV drip for 24 h, On the first 5 days, 21d is 1 cycle. After treatment for at least 2 cycles, the short-term efficacy and adverse reactions of the two groups of patients were evaluated. Results The total effective rate (RR) was 56.0% in SP group, including 1 case of complete remission (CR) and 13 cases of partial remission (PR). The RR of patients in FP group was 48.0%, including 1 case of CR and 11 cases of PR. Statistical significance (P>0.05). However, the clinical benefit rate (CBR) in the SP group was 84.0%, which was better than 68.0% in the FP group. The difference was statistically significant (P<0.05). The adverse reactions in the two groups were mainly myelosuppression, gastrointestinal reaction, abnormal liver function, and oral mucositis. Among them, nausea and vomiting were significantly higher in the FP group than in the SP group. The incidence of diarrhea was higher in the SP group than in the FP group (P<0.05). Conclusion The efficacy of the first-line treatment of advanced gastric cancer with the combination of tegapo and cisplatin is affirmative and the adverse reactions are mild.